Bausch + Lomb Corporation reported total revenue of $1.375 Billion for the third quarter of 2026, as compared to $1.281 billion in the third quarter of 2025, an increase of 7%. Excluding the ...

Bausch + Lomb Corp. ( BLCO ), a global eye health company, on Wednesday announced a return to profit for the third quarter of fiscal 2026, as revenue increased across all three business segments. The ...

In Q3, Bausch + Lomb reported adjusted EPS of $0.34, up from $0.18 in the same quarter last year. This comfortably beat analysts’ consensus estimates, a positive result for shareholders. Over the next ...

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market open. Here’s what to expect.

Bausch + Lomb announced that CEO and director Brent Saunders left the company and its board on October 12, 2026. Board ...

Bausch + Lomb (BLCO) has abruptly shifted its leadership, with CEO Brent Saunders departing and board chairman Thomas J.

Please provide your email address to receive an email when new articles are posted on . The partnership brings clinician-reviewed dry eye disease education and AI-guided symptom support to Verily Me.

Bausch + Lomb Corp. has appointed Thomas J. Appio interim CEO, succeeding Brent Saunders, who has led the company since 2023. Saunders and the board mutually agreed that he would depart from the ...

On October 12, 2026, Bausch + Lomb Corporation (Company) announced that Brent Saunders, Chief Executive Officer of the company and a member of the company?s board of directors, and the Board have ...

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, ...

Brent Saun­ders, one of bio­phar­ma’s most promi­nent deal­mak­ers and high­est-paid lead­ers, is out as CEO of Bausch + Lomb, fail­ing to add an­oth­er multi­bil­lion-dol­lar com­pa­ny sale to his ...